Why the study?
Glycemic control in young children is challenging, and most hybrid closed-loop devices are currently approved only with minimum age and daily insulin dose limits.
Does the advanced hybrid closed-loop system MiniMed 780G improve glycemic control and maintain safety in children with type 1 diabetes younger than 7 years old?
Does the advanced hybrid closed-loop system MiniMed 780G improve glycemic control and maintain safety in children with type 1 diabetes younger than 7 years old?
Answers are grounded in this paper and cite their sources.
The use of the advanced hybrid closed-loop system MiniMed 780G is safe and improves glycemic control in children under 7 years old with type 1 diabetes, even with a total daily insulin dose <8 units.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tornese et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: